GlassScriptPhysician profile
Bernard Schrager
NPI 1912964164
$2,495.90
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2020: $204 · 2021: $326 · 2022: $430 · 2023: $84.91 · 2024: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $298.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $514.38 | 2019-2020 | |
| Boston Scientific Corporation | $372.57 | 2022-2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $332.16 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $272.23 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $215.24 | 2019-2022 | |
| Amgen INC. | $196.52 | 2019-2022 | |
| Pfizer INC. | $172.58 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $162.39 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $96.65 | 2019 | |
| Esperion Therapeutics, INC. | $65.00 | 2021 | |
| Amarin Pharma, INC. | $32.05 | 2019-2020 | |
| United Therapeutics Corporation | $30.09 | 2023 | Tyvaso |
| Kiniksa Pharmaceuticals International, Plc | $20.99 | 2024 | Arcalyst |
| Allergan, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Schrager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.